FDA perspectives on potential microarray-based clinical diagnostics
<p>Abstract</p> <p>The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA anticipates tha...
Main Authors: | Težak Živana, Ranamukhaarachchi Daya, Russek-Cohen Estelle, Gutman Steven I |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-01-01
|
Series: | Human Genomics |
Subjects: | |
Online Access: | http://www.humgenomics.com/content/2/4/236 |
Similar Items
-
Chromosomal Microarrays in Prenatal Diagnosis: Time for a Change of Policy?
by: Peter Miny, et al.
Published: (2013-12-01) -
Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
by: Donald R. Love, et al.
Published: (2013-03-01) -
Implementation of molecular karyotyping in clinical genetics
by: Luca Lovrecic, et al.
Published: (2013-11-01) -
Evaluation of Chromosome Microarray Analysis in a Large Cohort of Females with Autism Spectrum Disorders: A Single Center Italian Study
by: Sara Calderoni, et al.
Published: (2020-10-01) -
Tube-Wise Diagnostic Microarray for the Multiplex Characterization of the Complex Plant Pathogen Ralstonia solanacearum
by: Gilles Cellier, et al.
Published: (2017-05-01)